Start Time: 19:30 January 1, 0000 8:10 PM ET Merck & Co., Inc. (NYSE:MRK) JPMorgan 42nd Annual Healthcare Conference January 08, 2024, 19:30 PM ET Company Participants Rob Davis - Chairman and CEO Dean Li - President, Merck Research Labs Conference Call Participants Chris Schott - JPMorgan Chris Schott Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Merck today. From the company, we have Rob Davis, Chairman and CEO; as well as Dean Li, President of Merck Resea ...

Start Time: 19:30 January 1, 0000 8:10 PM ET Merck & Co., Inc. (NYSE:MRK) JPMorgan 42nd Annual Healthcare Conference January 08, 2024, 19:30 PM ET Company Participants Rob Davis - Chairman and CEO Dean Li - President, Merck Research Labs Conference Call Participants Chris Schott - JPMorgan Chris Schott Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Merck today. From the company, we have Rob Davis, Chairman and CEO; as well as Dean Li, President of Merck Resea ...

Merck (MRK) closed at $117.38 in the latest trading session, marking a +0.14% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 1.41% for the day. Elsewhere, the Dow saw an upswing of 0.58%, while the tech-heavy Nasdaq appreciated by 2.2%.Heading into today, shares of the pharmaceutical company had gained 12.98% over the past month, outpacing the Medical sector's gain of 6.57% and the S&P 500's gain of 2.9% in that time.Analysts and investors alike will be keeping a cl ...

The shares of Merck & Co Inc (NYSE:MRK) are already 7.3% higher since the start of the year, and earlier hit a six-month high of $117.89 before turning lower. The pharma stock has been on an uptrend since bouncing off familiar support at the $100 level in late November, and just inched into positive territory year over year. The stock's rally could have legs, too, as its recent highs come amid historically low implied volatility (IV), which has been a bullish combination in the past. Per Schaeffer's Quantit ...

Merck (MRK) announced the initiation of pivotal phase III studies on four of its cancer candidates, most of which it added to its pipeline from the acquisitions and collaboration deals made in 2022. Patients are now actively enrolling in these studies.The first candidate is an LSD1 inhibitor, bomedemstat, for which a study called MK-3543-006 has begun for the treatment of certain patients with essential thrombocythemia (ET). Separately, multiple phase II studies are ongoing, which are evaluating bomedemstat ...

Merck (MRK) stock is shrugging off seven months of underperformance, shooting more than 7% higher in the first week of 2024 on growing excitement for its post-Keytruda life.X And, in the second week of 2024, Merck announced the $680 million takeover of Harpoon Therapeutics (HARP). Harpoon is working in a bread-and-butter area for Merck: immuno-oncology. Its drugs are designed to direct the body's own immune system to kill cancer cells. Harpoon stock ran up by triple digits early Monday, while Merck shares d ...

ljubaphoto Merck (NYSE:MRK) is an American pharmaceutical company whose medications and vaccines play key roles in the fight against viruses, cancer, and cardiovascular diseases. Thesis Over the past two months, Merck's share price has risen more than 17%, reflecting stock market euphoria about the expected Fed interest-rate cuts in 2024, a partnership with Daiichi Sankyo (OTCPK:DSKYF) to develop and subsequently commercialize three experimental antibody-drug conjugates showing promising results in clinical ...

Merck MRK, +0.18% is in talks to buy cancer drugmaker Harpoon Therapeutics HARP, -1.49% for about $700 million, or $23 per share, Bloomberg News reported, citing people familiar with the matter. Merck didn’t comment to Bloomberg, the report said, while Harpoon didn’t respond. Shares of Harpoon closed Friday at $10.55.  ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of pivotal Phase 3 trials for four of its investigational candidates from its diverse pipeline in hematologic malignancies and solid tumors. Global Phase 3 studies have been initiated and are actively enrolling for the following investigational candidates: Bomedemstat, an investigational orally available lysine-specific demethylase 1 (LSD1) inhibitor, being evaluated for t ...

Merck & Co., Inc. (NYSE:MRK) Goldman Sachs Healthcare C-Suite Unscripted Conference January 4, 2024 ET Company Participants Peter Dannenbaum - Head, IR Rob Davis - CEO Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani I suspect that people are going to be strolling in, but I don't like to penalize people who are on time, and let's try to stay on time. So let's get underway here. Welcome to what is by definition, in my opinion, the keynote presentation of this conference. We are th ...